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Abstract 
In this study, a series of nine novel 2-chloroquinolin-3-yl ester derivatives have been synthesized via a two-step protocol from 2-
chloroquinoline-3-carbaldehyde. The structures of all these compounds were confirmed by spectral data. The single crystal X-ray 
structure of two derivatives, (2-chloroquinolin-3-yl)methyl acetate [6a] and (2-chloro-6-methylquinolin-3-yl)methyl acetate [6e] have 
also been determined. The synthesized compounds were further evaluated for their ABTS radical-scavenging activity and 
  
antimicrobial activities. Amongst all the tested compounds, 6a exhibited maximum scavenging activity with ABTS. Concerning 
antibacterial and antifungal activities, compound (2-Chloro-6-methoxyquinolin-3-yl)methyl 2,4-dichlorobenzoate [6i] was found to be 
the most active in the series against B.subtilis, S.aureus, E. coli, K.pneumonia, C.albicans and A.niger species.The structure-
antimicrobial activity relationship of these derivatives were studied using Autodock. 
Keywords 
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1. Introduction 
Quinoline is a remarkable, interesting nitrogen heterocyclic scaffold of paramount importance to human race. Its skeleton is often an 
attractive framework in the design of several synthetic compounds against diverse pharmacological targets leading to the discovery of 
potent drugs. The chemistry of quinoline and its derivatives have been enjoying a relative renaissance of interest due to the growing 
abundance of quinoline components in various natural products, pharmaceuticals and new materials. The utility of quinoline 
derivatives in the areas of medicine [1], food, catalyst, dye [2], materials, refineries and electronics [3,4] is well established. These 
compounds are found to possess various bioactivities such as anti-malarial [5-7], anti-bacterial [8-11], anti-fungal [12-14], anti-cancer 
agents [15-18]. They are widely used as antibiotics [19], alkaloids, rubber, chemicals and flavoring agents. Additional industrial 
  
applications include their use as corrosion inhibitors, preservatives [20], solvents, resins, transition metal complex catalyst for uniform 
polymerization and luminescence chemicals [21]. The literature survey revealed that, the synthetic quinoline and substituted quinoline 
derivatives are associated with a wide range of biological properties in curing a lot of diseases. Amongst them, quinoline esters are one 
of the most important derivatives, however only few methods have been reported in the literature [22-32] for their synthesis. Recently, 
quinoline-4-methyl esters are found to serve as human non pancreatic secretory phospholipase A2 inhibitors [33] and quinoline 
dicarboxylic esters are used as biocompatible fluorescent tags [34]. As a result, the synthesis of quinoline and its derivatives have 
always attracted considerable attention especially from biochemists and synthetic organic chemists who are concerned with human and 
animal health care problems. In view of these observations and with a view to further explore the pharmacological profile of this class 
of compounds, the present study aims to put in considerable efforts to synthesize 2-chloroquinolin-3-yl ester derivatives, purify and 
characterize them.As quinoline and substituted quinoline derivatives are known to exhibit various biological activities such as 
antimicrobial, anti-inflammatory, analgesic, anti-tuberculosis, antiviral, the proposed research work is expected to result in the 
synthesis of biologically active of these derivatives.We also herein report, the crystal structures of two derivatives, the crystal structure 
analysis was carried out with the intention of eliciting structural information which could facilitate further understanding of structural 
requirements for improved biological activity, ABTS radical-scavenging activity and antimicrobial activity of the synthesized 
derivatives. 
Oxidative stress generates reactive oxygen species, such as superoxide (O-2), hydroxyl (OH-) and peroxyl (OOH-, ROO-) radicals, and 
are a crucial etiological factor to the pathophysiology of a variety of degenerative or pathological conditions such as ageing, cancer, 
  
coronary heart disease, Alzheimer’s disease, atherosclerosis and inflammation [35-36]. Human body has multiple mechanisms 
especially enzymatic and non-enzymatic antioxidant systems to protect the cellular molecules against reactive oxygen species (ROS) 
induced damage [37]. However due to the overproduction of reactive species and/or inadequate antioxidant defense, it culminates in 
severe or continued oxidative stress. The harmful action of the free radicals can, however be blocked by antioxidant substances, which 
scavenge the free radicals and detoxify the organism [38]. Many synthetic antioxidants such as butylated hydroxyl anisole (BHA) and 
butylated hydroxyl toluene (BHT) are very effective and have been added to food stuffs during food processing but they may possess 
toxic side effects and also acts as carcinogens [39]. Therefore there is a necessity to synthesize potent compounds that would have 
better scavenging activity and possess fewer side effects. 
Infectious diseases are threatening millions of people around the world and the recent upsurge in widespread antibiotic resistance 
among pathogens [40-42] and the undesirable side effects associated with constant use of drugs has prompted the search for novel 
antimicrobial agents. In virtual screening, a molecular docking played a crucial role in finding putative binding protein for a 
compound either from genomic or protein database [43]. Auto Dock 3 was used to perform the docking of a set of molecules 
withglucosamine-6-phosphate synthase(GlcN-6-P synthase), an elite target protein to inhibit the growth of microbes. This is the first 
report exploring the biological potential of these synthesized molecules as antimicrobial agents and providing evidence for 
exploitation of these compounds for further therapeutic applications. 
2. Experimental 
2.1. General Procedures 
  
Open capillary method was employed to determine the melting points and were found uncorrected. 1H and 13C NMR spectra were 
recorded on 400 MHz Brucker FT-NMR using TMS as the internal standard and CDCl3 as solvent. The chemical shifts are expressed 
in δppm. Mass spectra were recorded on LC-MS (Shimadzu QP 5000 spectrometer). CHN analysis was performed using vario 
MICRO CHN analyzer. Purity was checked by TLC. All chromatographic purifications were performed on 60-120silica gel columns 
by using 9.5:0.5 ratio of petroleum ether and ethyl acetate as eluent. Samples were crystallized from DCM or ethyl acetate. Chemicals 
and solvents used for the chemical synthesis were acquired from commercial sources of analytical grade. 
2.2. Synthesis of 2-chloroquinoline-3-carbaldehyde (4a) [44-55] 
To a stirred solutionof N-phenylacetamide(3a) (5mmoles) in dry DMF (15mmoles), POCl3 (60mmoles) was added drop-wise. The 
mixture was refluxed for overnight on water bath at 85-900C. The reaction mixture was quenched with crushed ice present in a 500 
mL beaker and stirred well for some time. The precipitate obtained was filtered, dried and purified by recrystallization processby using 
ethyl acetate to afford pure compound 4ain 82% yield. Similarly, the other aldehydes 4b-c were prepared by using the procedures 
reported earlier. 
2.3. Synthesis of (2-chloroquinolin-3-yl)methanol (5a) [56-59] 
To a stirred mixture of2-chloroquinoline-3-carbaldehydes (4a) (0.052 mol) in methanol (6 mL), NaBH4 (0.078 mol) was added portion 
wise under ice cold conditions for 15min. The reaction mixture was stirred for 30min. After the completion ofreaction, the reaction 
mixture was quenched with ice cold water and acidified very slowly with dil. HCl. The solid obtained was filtered, washed, dried and 
  
recrystallized from dichloromethaneto afford pure compound5ain 80% yield. Similarly, the other alcohols 5b-c were prepared by 
using the procedures reported earlier. 
2.4. Synthesis of (2-chloroquinolin-3-yl)methyl acetate (6a) 
A mixture of (2-chloroquinolin-3-yl)methanol (5a) (0.20g, 0.00095 mol) and acid chloride (0.21g, 0.0028 mol) was 
stirred in DMF along with activated K2CO3 at room temperature. The reaction was monitored by TLC. After 
completion of the reaction, the reaction mixture was quenched with ice cold water. The obtained solid was filtered, 
washed, dried and further purified by column chromatography using 9.5:0.5 mixture of petroleum ether and ethyl 
acetate to afford pure product 6a in 56% yield. Similarly, the other esters 6b-I were prepared (Table 1). 
Table 1. Synthesis of 2-chloroquinolin-3-yl ester derivatives (6a-i) 




























































o = overnight 
 
2.5. Spectral dataof(2-chloroquinolin-3-yl)methyl acetate derivatives(6a-i) 
2.5.1. (2-Chloroquinolin-3-yl)methyl acetate (6a) 
White crystalline; 1H NMR (400 MHz, CDCl3): δ = 2.18 (s, 3H), 5.35 (s, 2H), 7.56-7.57 (m, 1H), 7.73-7.75 (m, 1H), 7.84 (dd, J = 
1.20, 8.40 Hz, 1H), 8.02 (m, 1H), 8.20 (d, J = 0.40 Hz, 1H); 13C NMR (400 MHz, CDCl3):δ = 21.3, 63.5, 127.4, 127.8, 128.0, 128.2, 
128.8, 131.2, 138.5, 147.7, 150.1, 170.9; Positive LC-ESI-MS, m/z: 236.1 [M]+2, 237.3 [M]+3; Anal. Calcd for C12H10ClNO2: C, 61.16, 
H, 4.28, N, 5.94; Found: C, 61.05, H, 4.13, N, 5.79. 
2.5.2. (2-Chloroquinolin-3-yl)methyl benzoate (6b)  
Creamish white powder;1H NMR (400 MHz, CDCl3): δ = 5.65 (d, J = 0.8 Hz, 2H), 7.48-7.50 (m, 2H), 7.79 (s, 2H), 7.87 (t, J = 9.60 
Hz, 1H), 7.94-7.96 (m, 1H), 8.03-8.06 (m, 2H), 8.13 (t, J = 8.00 Hz, 1H), 8.58 (d, J = 8.2 Hz, 1H); 13C NMR (400 MHz, CDCl3):δ = 
  
63.5, 127.0, 127.4, 127.7, 128.0, 128.3, 128.4, 128.6, 128.8, 129.7, 129.8, 130.8, 133.4, 138.2, 147.4, 149.8, 166.1; Positive LC-ESI-
MS, m/z: 298.0 [M]+1; Anal. Calcd for C17H12ClNO2: C, 68.58, H, 4.06, N, 4.70; Found: C, 68.39, H, 4.19, N, 4.91. 
2.5.3. (2-Chloroquinolin-3-yl)methyl 2,4-dichlorobenzoate (6c) 
White Crystalline; 1H NMR (400 MHz, CDCl3): δ = 5.58 (s, 2H), 7.31-7.34 (m, 2H), 7.51 (t, J = 2.40 Hz, 1H), 7.58 (t, J = 2.00 Hz, 
1H), 7.88-7.90 (m, 3H), 8.22 (s, 1H); 13C NMR (400 MHz, CDCl3): δ = 64.4, 126.6, 126.7, 127.1, 127.2, 128.0, 131.2, 131.5, 132.9, 
133.3, 133.5, 136.0, 137.7, 138.3, 139.5, 146.0, 168.9; Positive LC-ESI-MS, m/z: 364.0[M]+1;  Anal. Calcd for C17H10Cl3NO2: C, 
55.69, H, 2.75, N, 3.82; Found: C, 55.47, H, 2.84, N, 3.92. 
2.5.4. (2-Chloroquinolin-3-yl)methyl 2,6-dichlorobenzoate (6d)  
White powder;1H NMR (400 MHz, CDCl3):δ = 5.67 (s, 2H), 7.27-7.29 (m, 3H), 7.56-7.57 (m, 1H), 7.73-7.74 (m, 1H), 7.84 (d, J = 
8.00 Hz, 1H), 8.03 (d, J = 8.40 Hz, 1H), 8.36 (s, 1H); 13C NMR (400 MHz, CDCl3): δ = 64.6, 126.6, 126.8, 127.0, 127.4, 127.7, 128.0, 
128.1, 128.4, 131.0, 131.3, 132.1, 133.0, 138.5, 147.4, 149.5, 164.4; Positive LC-ESI-MS, m/z: 365.8 [M]+1; Anal. Calcd for 
C17H10Cl3NO2: C, 55.69, H, 2.75, N, 3.82; Found: C, 55.49, H, 2.86, N, 3.90. 
2.5.5. (2-Chloro-6-methylquinolin-3-yl)methyl acetate (6e)  
White crystalline;1H NMR (400 MHz, CDCl3):δ = 2.18 (s, 3H), 2.54 (s, 3H), 5.33 (s, 2H), 7.60 (d, J = 4.8 Hz, 2H), 7.93 (d, J = 8.4 Hz, 
1H), 8.11 (s, 1H). 13C NMR (400 MHz, CDCl3): δ = 20.7, 27.2, 63.1, 126.5, 127.1, 127.7, 128.0, 133.0, 137.4, 137.5, 145.9, 148.7, 
170.5; Positive LC-ESI-MS, m/z:  250.0 [M]+1, 251.0 [M]+2; Anal. Calcd for C13H12ClNO2: C, 62.53, H, 4.84, N, 5.61; Found: C, 
62.17, H, 4.79, N, 5.66. 
  
2.5.6. (2-Chloro-6-methylquinolin-3-yl)methyl benzoate (6f)  
Yellow crystalline;1HNMR (400 MHz, CDCl3): δ = 2.56 (s, 3H), 5.61 (s, 2H), 7.28 (d, J = 2.00 Hz, 2H), 7.50 (t, J = 9.60 Hz, 3H), 
7.59-7.60 (m, 1H), 7.96 (d, J = 11.60 Hz, 2H), 8.13-8.16 (m, 1H); 13C NMR (400 MHz, CDCl3): δ = 24.0, 63.6, 126.6, 127.1, 127.8, 
128.0, 128.6, 129.8, 129.9, 130.3, 131.1, 133.1, 133.4, 137.5, 137.6, 146.0, 151.1, 166.2; Positive LC-ESI-MS, m/z: 312.0 [M]+1; 
Anal. Calcd for C18H14ClNO2: C, 69.35; H, 4.53, N, 4.49; Found: C, 69.47; H, 4.50, N, 4.41. 
2.5.7. (2-Chloro-6-methylquinolin-3-yl)methyl 2,6-dichlorobenzoate (6g)  
White crystalline;1H NMR (400 MHz, CDCl3): δ = 2.52 (s, 3H), 5.63 (s, 2H), 7.27-7.29 (m, 3H), 7.56 (t, J = 1.60 Hz, 2H), 7.90 (d, J = 
8.40 Hz, 1H), 8.25 (s, 1H); 13C NMR (400 MHz, CDCl3): δ = 21.6, 64.6, 126.1, 126.6, 126.8, 127.0, 128.0, 131.2, 132.1, 133.1, 133.2, 
135.2, 137.5, 137.9, 143.0, 146.0, 148.6, 164.3; Positive LC-ESI-MS, m/z: 382.0 [M]+2; Anal. Calcd for C18H12Cl3NO2: C, 56.80; H, 
3.18, N, 3.68; Found: C, 56.89; H, 3.26, N, 3.53. 
2.5.8. (2-Chloro-6-methoxyquinolin-3-yl)methyl acetate (6h)  
White powder;1H NMR (400 MHz, CDCl3):δ = 2.20 (s, 3H), 3.93 (s, 3H), 5.33 (s, 2H), 7.09 (s, 1H), 7.39 (dd, J = 2.68, 9.20 Hz, 1H), 
7.92 (d, J = 9.20 Hz, 1H), 8.10 (s, 1H); 13C NMR (400 MHz, CDCl3): δ = 20.9, 55.7, 63.1, 105.2, 123.4, 128.0, 128.2, 129.7, 136.8, 
143.3, 147.0, 158.4, 170.6; Positive LC-ESI-MS, m/z: 266.0 [M]+1, 267.0 [M]+2; Anal. Calcd for C13H12ClNO3: C, 58.77; H, 4.55, N, 
5.27; Found: C, 58.86; H, 4.58, N, 5.14. 
2.5.9. (2-Chloro-6-methoxyquinolin-3-yl)methyl 2,4-dichlorobenzoate (6i) 
  
Light brown powder;1H NMR (400 MHz, CDCl3):δ = 3.92 (s, 3H), 5.58 (s, 2H), 7.09 (d, J = 2.80 Hz, 2H), 7.33 (dd, J = 2.00, 8.40 Hz, 
1H), 7.39 (dd, J = 2.80, 9.20 Hz, 1H), 7.50 (d, J = 2.00 Hz, 1H), 7.89-7.91 (m, 1H), 8.20 (s, 1H); 13C NMR (400 MHz, CDCl3):δ = 
54.6, 63.4, 104.2, 122.6, 126.2, 126.4, 126.7, 127.1, 128.7, 130.2, 131.8, 134.2, 136.5, 137.9, 142.5, 146.1, 157.5, 163.3; Positive LC-
ESI-MS, m/z: 396.0 [M]+1; Anal. Calcd for C18H12Cl3NO3: C, 54.50; H, 3.05, N, 3.53; Found: C, 54.43; H, 3.09, N, 3.59. 
2.6.X-ray crystallography 
Single crystal of C12H10ClNO2 [6a] was obtained by slow evaporation of its ethyl acetate solution at 303 K and single crystal 
ofC13H12ClNO2[6e], by the slow evaporation of its dichloromethane solution at 283 K. A suitable crystal was selected and placed on a 
Nylon Loop on an Xcalibur, Eos, Gemini X-ray diffractometer. The crystal was kept at 173(2) K during data collection. Using Olex2 
[60], the structure was solved with the Superflip [61] structure solution program using Charge Flipping and refined with the ShelXL 
[62] refinement package using Least Squares minimization. The details are presented in Table 2. 




Crystal Data for C12H10NO2Cl (M =235.66): Monoclinic, space group P21/c (no. 14), a = 8.1324(4) Å, b = 10.9545(4) Å, c = 
12.1817(5) Å, β = 93.323(4)°, V = 1083.40(8) Å3, Z = 4, T = 173(2) K, μ(MoKα) = 0.335 mm-1, Dcalc = 1.445 g/mm3, 13335 
reflections measured (6.7 ≤ 2θ ≤ 65.78), 3727 unique (Rint = 0.0303) which were used in all calculations. The final R1 was 0.0421 (I 
>2σ(I)) and wR2 was 0.1160 (all data). 
2.6.2. Crystal structure determination of [6e]  
 
Crystal Data for C13H12ClNO2 (M =249.69): Monoclinic, space group P21/c (no. 14), a = 24.0571(7) Å, b = 7.5420(2) Å, c = 
13.6211(4) Å, β = 103.070(3)°, V = 2407.37(12) Å3, Z = 8, T = 173(2) K, μ(CuKα) = 2.724 mm-1, Dcalc = 1.378 g/mm3, 13833 
reflections measured (11.328 ≤ 2θ ≤ 144.99), 4705 unique (Rint = 0.0359) which were used in all calculations. The final R1 was 0.0587 
(I >2σ(I)) and wR2 was 0.1642 (all data). 
 
  
2.7. ABTS assay [63] 
ABTS [2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)] Radical Cation Scavenging Method. 
Principle: 
The pre-formed radical mono cation of 2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) is generated by oxidation of ABTS with 
potassium persulfate (a blue chromogen) and is reduced in the presence of such hydrogen donating antioxidants.  
Chemicals and Reagents Used: 
Preparation of ABTS solution  
Solution I: ABTS (2, 2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (2 mM solution is prepared using distilled water). 
Solution II: Potassium persulfate (17mM solution is prepared using distilled water) 
 0.3 mL of solution II was added to 50 mL of solution I. The reaction mixture was left to stand at room temperature overnight in dark 
before use.  
Preparation of Test Solution 
5mg of each of the drug samples and the standard (ascorbic acid) were accurately weighed separately and dissolved in 1mL of 
Dimethyl sulphoxide (DMSO).   
Method  
  
1 mL of distilled DMSO was added to 0.2 mL of various concentrations of the drug samples or standard, and 0.16 mL of ABTS 
solution was added to make a final volume of 1.36 mL. The absorbance was measured spectrophotometrically, after 7min at 734 nm 
using a Spectrophotometer.  Blank was maintained without ABTS.  
The radical scavenging activity (%) is calculated by the following formula, 
(Absorbance of control – Absorbance of sample) X 100  
Absorbance of control 
2.7.1. Bacterial susceptibility testing 
In vitro antibacterial activity of synthesized compounds was studied against Gram-negative and Gram-positive bacteria by the agar 
well diffusion [64]. Nutrient agar (Hi Media, India) was used as the bacteriological medium. The compounds were dissolved in 10% 
aqueous dimethylsulfoxide (DMSO) to a final concentration of 100µg/100µL. Pure DMSO was taken as the negative control and 
100µg/100µL Streptomycin as the positive control.  
100 μL of inoculum was aseptically introduced on to the surface of sterile agar plates and sterilized cotton swabs were used for the 
even distribution of the inoculum. Wells were prepared in the agar plates using a sterile cork borer of 6.0 mm diameter. 100 μLof test 
and control compound were introduced in the well. The same procedure was used for all the strains. The plates were incubated 
aerobically at 35οC and examined after 24h[65-66]. The diameter of the zone of inhibition produced by each agent were measured with 
a ruler and compared with those produced by the commercial antibiotic Streptomycin. 
2.7.2. Fungal susceptibility testing 
  
The antifungal activity of the synthesized compounds was tested using agar well diffusion method. The potato dextrose agar plates 
were inoculated with each fungal culture (10 days old) by point inoculation. A well of about 6.0 mm diameter with sterile cock borer 
was aseptically punched on each agar plate. The synthesized test compound (100µg/100µL) was introduced into the well; a negative 
control well was too made with 100μL of the solvent DMSO and 100µg/100µLNystatin as the positive control. Plates were kept in 
laminar flow for 30 minutes for pre diffusion of compound to occur and then incubated at 280C for 48h. Resulting zone of inhibition 
(in mm) was measured using a Hi media zone scale [67]. 
2.8. Molecular docking studies 
Automated docking was used to determine the orientation of inhibitors bound in the active site of GlcN-6-P synthase as target for 
antimicrobial activity. A Lamarckian genetic algorithm method, implemented in the program AutoDock 3.0, was employed. The 
ligand molecules (6a-i) were designed and the structure was analyzed by using ChemDraw Ultra 6.0. 3D coordinates were prepared 
using PRODRG server [68]. The protein structure file (PDB ID: 1XFF) was taken from PDB (www.rcsb.org/pdb) was edited by 
removing the hetero-atoms, adding C terminal oxygen [69]. For docking calculations, Gasteigere – Marsili partial charges [70] were 
assigned to the ligands and non-polar hydrogen atoms were merged. All torsions were allowed to rotate during docking. The grid map 
was centered at particular residues of the proteins which was predicted from the ligplot and were generated with AutoGrid. The 
Lamarckian genetic algorithm and the pseudo-Solis and Wets methods were applied for minimization, using default parameters [71]. 
  
3. Results and Discussion  
3.1. For synthesis 
Synthesis of the derivatives (6a-i) was carried out as depicted in Scheme 1. Quinoline carbaldehydes(4a-c) were synthesized through 
traditional Vilsmeier-Haack cyclization [35-46] of acetanilides (3a-c) [72]. These compounds were then reduced using NaBH4 in 
methanol to yield (2-chloroquinolin-3-yl)methanol derivatives (5a-c). The analytical data of the compounds 4a-c and 5a-c was 
compared with the reports available in the literature [44-59]. The strategy employed for the synthesis of compounds (6a-i) is almost 
similar to that reported earlier [73]. Various quinoline ester derivatives (6a-i) were prepared by coupling alcohols (5a-c) with various 
acid chlorides in the presence of K2CO3 in DMF (Table 1). The IR spectra of compounds (6a-i) showed a peak around at 1750 cm-1 
due to C=O stretching. The 1H NMR spectra of compound 6a showed a shift at δ = 3.92 (s, 3H) for the protons CH3CO. The LC-MS 
m/z value of [M]+2 was obtained at 236.1. Finally the 13C NMR spectra of the compound 6a showed a signal at nearly δ = 170 ppm for 
the carbonyl group. The detailed procedure and the analytical data for all the derivatives (6a-i) are placed in experimental section. The 
crystal structures of the compounds 6a and 6e were also determined. Further, supporting data for all the final derivatives 6a-i, i.e. 




































3.2. X-ray Crystal Structure Analysis 
3.2.1. (2-Chloroquinolin-3-yl)methyl acetate (6a) 
In C12H10NO2Cl, the dihedral angle between the mean planes of the 2-chloroquinolin-3-yl and the carboxylate group 
(C10\O1\C11\O2) is 12.8(5)o(Fig.1).  
  
 
Fig 1. Molecular structure of C12H10NO2Cl showing the atom labeling scheme and 50% probability displacement ellipsoids. 
Bond lengths are in normal ranges [74] (Table 2a).  In the crystal, weak C7---H7…N1 intermolecular interactions (Table 3) link the 







Fig 2. Packing diagram of C12H10NO2Clviewed along a-axis. Dashed lines indicate weak C7---H7…N1 intermolecular 
interactions link the molecules into tetramers and influence the crystal packing. The remaining H atoms have been deleted for 
clarity. 
Table 2a. Selected Crystal Bond Lengths (Å), Bond angles (o), and Torsion angles (o) forC12H10NO2Cl 
           _____________________________________________________________ 
 
    C(l1)-C(1)                   1.7468(13)   
     C(1)-C(2)                    1.4181(16) 
                      O(1)-C(10)                   1.4356(15)  
      C(2)-C(10)                    1.5018(17) 
                      O(2)- C(11)                   1.1953(18)   
                      C(5)-C(6)                     1.3702(19) 
                      N(1)-C(1)                     1.2987(16) 
                       C(11)-C(12)                   1.492(2) 
 
  
                   C(11)- O(1)- C(10)               117.29(10)  
                   C(1)- N(1)- C(9)                 117.13(11) 
                   N(1)- C(1)- Cl(1)                115.66(9) 
N(1)- C(1)- C(2)                 126.70(12) 
                   C(2)- C(1)- Cl(1)                117.63(9)   
                   C(3)- C(2)- C(1)                 116.05(11) 
                   N(1)- C(9)- C(4)                 121.62(11) 
                   N(1)- C(9)- C(8)                 119.11(12) 
                   O(1)- C(11)- C(12)               110.51(12) 
                   O(2)- C(11)- O(1)                123.07(13) 
                   O(2)- C(11)- C(12)               126.41(13) 
                   O(1)- C(10)- C(2)                106.56(10) 
                  Cl(1)- C(1)- C(2)- C(3)           178.47(9)         
                  Cl(1)- C(1)- C(2)- C(10)         -1.86(15) 
                  N(1)- C(1)- C(2)- C(3)           -0.17(18) 
                  N(1)- C(1)- C(2)- C(10)           179.50(11) 
                  C(1)- N(1)- C(9)- C(4)            0.58(17)  
                  C(1)- N(1)–C(9)- C(8)            -179.53(11) 
                  C(10)- O(1)- C(11)- O(2)         -0.8(2) 
                  C(10)- O(1)- C(11)- C(12)         178.40(11) 
                  C(10)- C(2)- C(3)- C(4)          -178.66(11)  
                  C(11)- O(1)- C(10)- C(2)          177.23(10) 







Table 2b. Selected Crystal Bond Lengths (Å), Bond angles (o), and Torsion angles (o) for C13H12ClNO2 
           _____________________________________________________________ 
 
Cl(1A)- C(4A)   1.754(3) 
O(1A)- C(1A)   1.195(4) 
O(2A)- C(1A)   1.337(3) 
N(1A)- C(4A)   1.289(3) 
C(1A)- C(13A)   1.491(4) 
C(8A)- C(9A)   1.364(4) 
Cl(1B)- C(4B)   1.750(3) 
O(1B)- C(1B)   1.196(3) 
O(2B)- C(2B)                    1.442(3) 
N(1B)- C(5B)                    1.375(4) 
C(1B)- C(13B)                    1.498(4) 
C(1A)- O(2A)- C(2A)              115.7(2) 
C(4A)- N(1A)- C(5A)              117.1(2) 
O(1A)- C(1A)- O(2A)              122.9(3) 
O(2A)- C(1A)- C(13A)             111.4(3) 
C(11A)- C(3A)- C(2A)             124.1(2) 
C(11A)-C(3A)- C(4A)              115.2(2) 
N(1A)- C(4A)- Cl(1A)             115.83(19) 
N(1A)- C(4A)- C(3A)              127.2(2) 
C(1B)- O(2B)- C(2B)              114.7(2) 
C(4B)- N(1B)- C(5B)              117.0(2) 
O(1B)- C(1B)- O(2B)              123.5(3) 
O(2B)- C(1B)- C(13B)             111.3(2) 
C(11B)-C(3B)- C(2B)             124.9(2) 
C(11B)- C(3B)- C(4B)             115.3(2) 
N(1B)- C(4B)- Cl(1B)             115.97(19) 
N(1B)- C(4B)- C(3B)              127.1(2) 
  
O(2A)- C(2A)- C(3A)-C(4A)        171.9(2) 
O(2B)- C(2B)- C(3B)- C(4B)       172.6(2) 
N(1A)- C(5A)- C(6A)- C(7A)       -177.6(2) 
N(1B)- C(5B)- C(6B)- C(7B)       -177.3(2) 
N(1A)- C(5A)- C(10A)- C(11A)     -1.6(3) 
N(1B)- C(5B)- C(10B)- C(11B)     -1.3(4) 






Table 3. Non-bonded interactions and possible hydrogen bonds in C12H10NO2Cl & C13H12ClNO2 (Å, °). 








Symmetry transformations used to generate equivalent atoms:i) 1-x,-1/2+y,1/2-z;   ii)  1-x,-y,1-z 























In C13H12ClNO2, two independent molecules [A and B] crystallize in the asymmetric unit.  The dihedral angle between the mean 
planes of the 2-chloro-6-methylquinolin-3-yl and the carboxylate group is 10.9(3)o[A] and 7.0(9)o [B] (Fig.3).  
 
Fig 3. Molecular structure of C13H12ClNO2 showing the atom labeling scheme with two molecules (A and b) in the asymmetric 
unit and 30% probability displacement ellipsoids.  
Bond lengths are in normal ranges [74] (Table 2b).  The chlorine atoms in [A] and [B] are slightly deviated from the mean planes of 
the 2-chloro-6-methylquinolin-3-ylrings by 2.9(9)o and 2.8(8)o, respectively.In the crystal, weak C7B---H7B…O1A intermolecular 
interactions (Table 3) link the molecules into dimers along [100] (Fig. 4).  
  
 
Fig 4.  Packing diagram of "C13H12ClNO2" viewed along the b axis. Dashed lines indicate weak C7B---H7B…O1A 
intermolecular interactions link the molecules into dimers along [100]. The remaining H atoms have been deleted for clarity. 
In addition Cg1--Cg1π—π intermolecular interactions are observed and contribute to crystal packing (Cg1—Cg1 = 3.8029(13) Å; 2-x, 
-y, 1-z; Cg1 = N1A/C4A/C3A/C11A/C10A/C5A). 
 
3.3. For ABTS radical-scavenging activity and Antimicrobial Activity 
The ABTS radical-scavenging activityof the compounds (6a-i) revealed that amongst all the tested compounds, 6a and 6g exhibited 
maximum scavenging activity with ABTS. Compounds 6d-fand 6h, exhibited similar activity (Table 4). 
  
Table 4. ABTS radical-scavenging assay of (6a-i) derivatives 





























3.3.1. Antimicrobial Studies 
The synthesized compounds were effective in controlling the growth of clinical strains tested (Table 5). The study revealed 
that the antibacterial activity of compound 6i was highest with zone of inhibition in the range of 32.24±0.18 to 18.67±0.69. The lowest 
inhibition values were recorded by compound6g (13.87 ± 0.28 to 5.53 ± 0.24). The rest of the compounds i.e., 6a-f and 6h showed 
moderate activity. Staphylococcus aureus was the most susceptible and Klebsiellapneumoniae, the least amongst all the bacterial 
  
strains investigated in the present work. Streptomycin which was used as positive experimental control against strains assayed, 
produced a zone of inhibition of 45.33±0.63 to 28.53±0.17, while no inhibitory effect could be observed for DMSO used as negative 
control.  
All the compounds exhibited different antifungal activity in vitro against the tested fungal strains (Table 5). Of these fungal 
strains, Candida albicanswas more resistant to the synthesized compounds than Aspergillusniger. All the compounds produced the 
inhibitory zones; the most active compound being 6i with maximum zone of inhibition in the range of 20.53±0.66 to 16.67 ± 0.84 
followed by the compounds 6f, 6b, 6h, 6d, 6a, 6c, 6e; and 6g exhibited minimum antifungal activity (6.67 ± 0.16 to 4.87 ± 0.22), 
when compared with Nystatin (29.53±0.33 to 24.73±0.57). 
Hence, it is apparent that they have been found to be effective antimicrobial substances against a wide range of 
microorganisms. Their activity is probably due to their ability to react with extracellular and soluble proteins and to complex with 
bacterial cell walls [75]. From the results it can be concluded that 6i is more effective than 6g and proved to be a better antimicrobial 
agent of the nine compounds and can be used as a leading molecule in drug design i.e., in inhibiting these medically important 
microbial strains. Such screening of various compounds and identifying the active agents is essential because the successful prediction 










Bacterial strains Fungal strains 






Streptomycin 32.66±0.33 45.33±0.63 30.68±0.22 28.53±0.17 _ _ 
Nystatin _ _ _ _ 24.73±0.57 29.53±0.33 
6a 16.00±0.56 20.20 ± 0.14 14.00 ± 0.15 11.67 ± 0.33 10.67 ± 0.59 14.00 ± 1.19 
6b 18.73±0.19 23.27 ± 0.55 15.67 ± 0.33 13.73 ± 0.10 12.00 ± 0.04 16.00 ± 0.27 
6c 13.53 ± 0.28 18.20 ± 0.14 11.33 ± 0.32 10.67 ± 0.34 8.33 ± 0.16 11.07 ± 0.50 
6d 17.33 ± 0.29 21.87 ± 0.28 14.67 ± 0.58 12.00 ± 0.66 11.00 ± 0.92 14.67 ± 0.58 
6e 12.67 ± 0.53 17.67 ± 0.69 10.33 ± 0.32 9.87 ± 0.18 7.67 ± 0.25 10.00 ± 0.92 
6f 19.53 ± 0.01 24.53±0.17 16.00 ± 0.56 14.67 ± 0.51 12.77 ± 0.30 16.67 ± 0.63 
6g 10.60 ± 0.23 13.87 ± 0.28 7.67 ± 0.25 5.53 ± 0.24 4.87 ± 0.22 6.67 ± 0.16 
6h 18.00 ± 0.63 22.73 ± 0.20 15.00 ± 0.36 12.33 ± 0.19 11.47 ± 0.16 15.33 ± 0.40 
6i 24.27 ± 0.30 32.24±0.18 20.87±0.30 18.67±0.69 16.67 ± 0.84 20.53±0.66 




3.4. Docking studies 
The docking of 6a-i derivatives with Glutamine amido transferase domain reveals that, our 
synthesized molecule which are having inhibitory capability are exhibiting the interactions with 
one or the other amino acids in the active pockets which is showed in Fig 5.  
Fig 5. Enfolding of synthesized molecules in the active pocket 
    
 





    
 
    
 






The docking results for inhibitor compounds are documented in Table 6. 









H- bonds Bonding 








6c -8.78 -10.13 3.65-007 -10.03 3 6c::DRG1:OAO:GPS:B:ARG217:HH22 
6c::DRG1:OAO:GPS:B:ARG216:HH22 
6c::DRG1:OAO:GPS:B:ARG216:HH12 




6e -7.84 -8.81 1.8e-006 -8.77 3 6e::DRG1:OAP:GPS:B:GLN9:HN 
6e::DRG1:OAP:GPS:B:ARG10:HN 
6e::DRG1:NAH:GPS:A:GLU14:OE1 




6g -9.25 -11.01 1.65e-007 -10.5 2 6g::DRG1:OAL:GPS:B:GLY183:O 
6g::DRG1:OAO:GPS:B:ARG202:HH22 

























Practically, all the nine molecules showed good binding energy and docking energy ranging from 
-7.84 kJmol-1 to -10.36 kJmol-1 and -8.81 kJmol-1 to -11.01 kJmol-1 respectively. Amongst the 
nine molecules, docking of GlcN-6-P synthase with 6i revealed five hydrogen bonds and its 
binding energy and docking energy were -9.71 kJmol-1 and -10.98 kJmol-1 respectively and it 
may be considered as good inhibitor of GlcN-6-P synthase. All the synthesized molecules were 
completely enfolded in the entire active pocket of GlcN-6-P synthase (Fig 5). The topology of 
the active site of GlcN-6-P synthase was similar in all the synthesized molecules, which is lined 



















Fig 6. Interacting amino acids as predicted from the ligplot. 
In vitro studies reveals that6i has emerged as an active molecule against all the screened 
microorganisms, so it can be predicted that the activity may be due to the inhibition of enzyme 
GlcN-6-P synthase, which catalyzes a complex reaction involving ammonia transfer from L-
glutamine to Fru-6-P, followed by isomerization of the formed fructosamine-6-phosphate to 
glucosamine-6-phosphate. Hence, this study has provedthat molecule6ito be one of the potent 
antibacterial and antifungal agent. 
Conclusion 
Starting from aniline, novel substituted quinoline derivatives (6a-i) were synthesized with 
moderate to excellent yields. The obtained products were thoroughly characterized by spectral 
techniques. The crystal and molecular structure of the two compounds (6a and 6e) have been 
determined. Weak interactions and supramolecular assembly, involving several hydrogen 
bonding interactions of different functional groups have been demonstrated. It is observed that 
the crystal structure of the two compounds is stabilized by strong intermolecular C-H…N and C-
H…O hydrogen bonds. Additionally the supramolecular assembly is consolidated by special type 
of Cg-Cg (π-ring) interaction. The structure analysis of these compounds provides an insight into 
the correlation between molecular structures and intermolecular interactions in compounds for 
drug development. Some of these derivatives were found effective against tested organisms. This 
provides further scope for evaluation of this class of compounds for other biological activities 
and also in particular with data pertaining to structure-activity relationships. It is also expected 
that the drugs synthesized using the above would pave a new way for the planning, designing 




Appendix A. Supplementary data 
CCDC 972576 and 972577 contains the supplementary crystallographic data for C12H10NO2Cl 
and C13H12ClNO2. These data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic Data 
Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax:(+44) 1223-336-033; or email: 
deposit@ccdc.cam.ac.uk. 
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Fig 5. Enfolding of synthesized molecules in the active pocket 
 6a   6g 
 










































Highlights of Research 
• Synthesis of nine novel 2-chloroquinolin-3-yl ester derivatives using 
readily available, inexpensive and environmental friendly base catalyst. 
• All these nine compounds were thoroughly characterised by 1H NMR, 13C NMR 
spectroscopy, LCMS spectrometry, elemental analysis and melting point analysis. 
• The present method is the simplest and best available to date for synthesis of these 
individually novel quinoline derivatives. 
• Two of these were obtained as single crystals and their crystal structures were studied. 
• Some of these compounds have shown prominent antimicrobial and antioxidant activity. 
• The docking studies were carried out for all the nine compounds. 
 
 
 
